Market Expansion Valeant Pharmaceuticals has actively expanded its portfolio through acquisitions, including Bausch + Lomb and AcneFree, suggesting opportunities to offer complementary healthcare and pharmaceutical products to support their growth strategy.

Regulatory Challenges Recent legal and ethical issues related to accounting, pricing practices, and bribery charges indicate potential areas where compliance solutions, legal consulting, or transparency-enhancing services could be valuable for the company.

Product Innovation The launch of new pharmaceutical products like flibanserin (Addyi) after acquisitions highlights a focus on product development; this presents opportunities to introduce innovative drug formulations, research collaborations, or manufacturing support.

Technology Utilization Valeant's use of digital tools such as Google Analytics and ASP.NET demonstrates an openness to digital solutions, opening doors for sales of advanced analytics, customer engagement platforms, or IT infrastructure services.

Financial Growth With revenues ranging from $250M to $500M and a history of major acquisitions, the company may require financial management tools, M&A advisory, or strategies for optimizing revenue streams and scaling operations efficiently.